Evidence map›Paper›PMID 32764809›Full record

ArticlePloS one2020

Rapid genotyping protocol to improve dengue virus serotype 2 survey in Lao PDR.

Elodie Calvez, Somphavanh Somlor, Souksakhone Viengphouthong, Charlotte Balière, Phaithong Bounmany, Sitsana Keosenhom, Valérie Caro, Marc Grandadam

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elodie CalvezInstitut Pasteur du Laos, Vientiane, Lao People's Democratic Republic.ORCID 0000-0002-5772-8161
Somphavanh SomlorInstitut Pasteur du Laos, Vientiane, Lao People's Democratic Republic.
Souksakhone ViengphouthongInstitut Pasteur du Laos, Vientiane, Lao People's Democratic Republic.
Charlotte BalièreInstitut Pasteur, Paris, France.
Phaithong BounmanyInstitut Pasteur du Laos, Vientiane, Lao People's Democratic Republic.
Sitsana KeosenhomInstitut Pasteur du Laos, Vientiane, Lao People's Democratic Republic.
Valérie CaroInstitut Pasteur, Paris, France.
Marc GrandadamInstitut Pasteur du Laos, Vientiane, Lao People's Democratic Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue fever is one of the major public health problems in Lao PDR. Over the last decade, dengue virus (DENV) epidemics were characterized by a novel predominant serotype accompanied by at least two other serotypes. Since 2008, DENV-2 circulated at a low level in Lao PDR but its epidemiologic profile changed at the end of 2018. Indeed, the number of confirmed DENV-2 cases suddenly increased in October 2018 and DENV-2 became predominant at the country level in early 2019. We developed a Genotype Screening Protocol (GSP) to determine the origin(s) of the Lao DENV-2 and study their genetic polymorphism. With a good correlation with full envelope gene sequencing data, this molecular epidemiology tool evidence the co-circulation of two highly polymorphic DENV-2 genotypes, i.e. Asian I and Cosmopolitan genotypes, over the last five years, suggesting multiple introductions of DENV-2 in the country. GSP approach provides relevant first line information that may help countries with limited laboratory resources to reinforce their capabilities to DENV-2 and to follow the epidemics progresses and assess situations at the regional level.

Indexed as

Surveys and QuestionnairesDengue VirusGenotyping TechniquesHumansLaosSerotypingTime FactorsUrban Population

Identifiers

PMID32764809
PMCPMC7413503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.